Article Details
Retrieved on: 2022-07-27 06:48:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The Goldman Sachs Group assumed coverage on Vor Biopharma in a report on Wednesday, April 27th. They set a “neutral” rating and a $6.00 price target ...
Article found on: reporter.am
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here